Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and
Drug Administration for prophylaxis of venous thromboembolism in adult patients …

Abstract 2266 Betrixaban is a once daily oral Factor Xa inhibitor being investigated in a
Phase 3 clinical trial to prevent venous thromboembolism in acute medically ill patients …

Introduction: Compared to other direct oral anticoagulants, betrixaban has a longer half-life,
smaller peak-trough variance, minimal renal clearance, and minimal hepatic Cytochrome P …

Interpatient variability in the safety and efficacy of oral anticoagulation with warfarin presents
several challenges to clinicians, thus underscoring the emergent need for new orally …

Approximately 900,000 people are affected by some sort of venous thromboembolic (VTE)
event every year in the United States. VTE diagnosis used to mean treatment with …

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), remains a preventable cause of morbidity and mortality in hospitalized …

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective
and safe antithrombotic treatments are a public health priority. New antithrombotics such as …

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level
monitoring are presently undergoing taut scrutiny for efficacies and potential side effects …

Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-
hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and …

For years, prevention and treatment of thromboembolic events have been restricted to the
use of heparins and vitamin K antagonists. These treatments, in spite of their unquestioned …